{"prompt": "['61', '29. Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, Waterman C,', 'Ulbrecht JS, Cavanagh PR, Boulton AJ. Predictors of depressive symptoms in persons', 'with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009; 52: 1265-', '73.', '30. Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A,', 'Waterman C, Cavanagh PR, Boulton AJ. Diabetic peripheral neuropathy and depressive', 'symptoms: the association revisited. Diabetes Care. 2005; 28:2378-83.', '31. Vileikyte L, Peyrot M, Bundy C, Rubin RR, Leventhal H, Mora P, Shaw JE, Baker P,', 'Boulton AJ. The development and validation of a neuropathy-and foot ulcer-specific', 'quality of life instrument. Diabetes Care. 2003; 26:2549-55.', '32. Kubat N, Moffett J, Fray L. Effect of pulsed electromagnetic field treatment on', 'programmed resolution of inflammation pathway markers in human cells in culture. J', 'Inflamm Res 2015; 8:59-69.', '33. American Diabetes Association. Diabetes Care 2018 Jan; 41 (Supplement 1): S13-S27.', '34. Kasperczak J, Ropacka-Lesiak M, Breborowicz HG. Definition, classification and', 'diagnosis of chronic venous insufficiency. Ginekol Pol. 2013; 84(1):51-5.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['62', 'APPENDIX A: TIME AND EVENTS SCHEDULE', 'Part A', 'Part B', 'Screening', '14-day', 'Enrollment', 'Day 7', 'M1', 'M2', 'M3', 'M4', 'M5', 'M6', 'M7', 'M8', 'M9', 'M10', 'M11', 'M12', 'Period', 'Visit', 'Run-In', '(Baseline)', 'Call', 'Visit', 'Visit', 'Visit', 'Visit', 'Call', 'Call', 'Call', 'Visit', 'Call', 'Call', 'Call', 'Visit', 'Study Day', '-15', '0', '7 (+2)', '30 (3)', '60 (+3)', '90 (=3)', '121 (+3)', '150 (3)', '180 (=3)', '210 (3)', '240 (+3)', '270 (+3)', '300 (3)', '330 (=3)', '361 (=3)', 'Informed Consent', 'X', 'Demographic Information', 'X', 'Medical/Surgical History/Physical Exam', 'X\u00b3', 'Inclusion/Exclusion Criteria', 'X', 'X\u00b9', 'Baseline Health Economics', 'X', 'Pain Score Assessment (NPRS)', 'X', 'X\u00b2', 'Measurement of Foot Thickness, Width, and', 'X', 'Length', 'Height and Weight', 'X', 'X5', 'Urine Pregnancy Test', 'X4', 'Measure HbAlc', 'Obtain Ankle-Brachial Index & Assess', 'Venous Insufficiency', 'ePRO Diary (pain scores, analgesic use)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Assess Adherence to treatment regimen and', 'X7', 'X', 'X', 'X', 'X', 'X8', 'X', 'X8', 'X', 'X8', 'X', 'X8', 'ePRO entries', 'Toronto Clinical Neuropathy Scoring System', 'X', 'X', 'Randomize and Dispense Study Device', 'X', '3mm Skin Punch Biopsy at distal leg and', 'X', 'X', 'distal thigh', 'WPAIQ', 'X', 'X', 'NeuroQoL Questionnaire', 'X', 'X', 'X', 'Skin Perfusion Pressure (SPP)', 'X', 'X', 'X', 'Quantitative Sensory Test (QST) thermal', 'X', 'Sural Nerve Conduction Studies (NCS)', 'X', 'Study Device Training', 'X', 'Assess Biopsy Treatment Site', 'Study Device Blinding Assessment', 'X', 'Assess Adverse Events', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'X6', 'Assess Concomitant Medications', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Patient Global Impression (PGI)', 'X', 'X', 'X', 'Review Device Usage Report', 'X', 'Treatment Satisfaction', 'X', 'Return Study Device', 'Enroll Subject in Part B of protocol in ePRO', 'and dispense device', '1.', 'Inclusion/Exclusion criteria must be reviewed to ensure patient continues to qualify for the study.', '2.', 'Average pain score over the 7 days preceding the visit will be calculated in the EDC system and verification of inclusion pain score >4 and <9 and compliance of >70% will be determined at the Enrollment Visit.', '3.', 'Medical History will be reviewed at the Enrollment Visit for any changes.', '4.', 'Urine pregnancy test will be performed on women of child-bearing potential.', '5.', 'Weight will be measured at the end of Part A and at the end of Part B.', '6.', 'Assessment of adverse events will be conducted after the signing of the Informed Consent.', '7.', 'Adherence to ePRO entries will be assessed at the Enrollment Visit for inclusion.', '8.', 'Adherence to diary completion will be completed at the 6M, 8M, 10M, and 12M visits.', '710-7105-01 C', 'Protocol RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}